Mesa Laboratories, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2017. The request metadata identifies “2015 Q4,” but the supplied filing is the fiscal 2017 Form 10-K, not a 2015 quarterly filing.
Business context
Mesa develops and sells quality-control products and services serving regulated niche markets. Its four divisions are Biological Indicators, Instruments, Cold Chain Monitoring, and Cold Chain Packaging. Revenue is generated from product sales and services, with approximately 57% of fiscal 2017 revenue from U.S. customers and 43% from foreign customers.
The company completed six acquisitions during fiscal 2017, primarily expanding biological-indicator testing and distribution, cold-chain monitoring, and cold-chain packaging.
Financial performance and liquidity
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| Revenue | $93.665 million | $84.659 million | 11% |
| Gross profit | $53.239 million | $51.413 million | 4% |
| Gross margin | 57% | 61% | Down 4 points |
| Operating income | $16.313 million | $16.323 million | Flat |
| Operating margin | 17% | 19% | Down 2 points |
| Net income | $11.183 million | $11.169 million | Flat |
| Diluted EPS | $2.91 | $2.97 | Down 2% |
| Adjusted net income | $16.228 million | $15.324 million | 6% |
| Adjusted diluted EPS | $4.22 | $4.08 | 3% |
| Operating cash flow | $7.750 million | $16.903 million | Down $9.153 million |
| Capital expenditures | $11.605 million | $7.729 million | Up $3.876 million |
| Cash and equivalents | $5.820 million | $5.695 million | Up $0.125 million |
| Working capital | $19.218 million | $13.215 million | Up $6.003 million |
At March 31, 2017, total debt was $55.25 million before debt discounts, consisting of a $35.5 million revolving line and $19.75 million term loan. As of June 5, 2017, outstanding indebtedness was $52.25 million with $47.5 million of unused credit capacity. Debt bears variable interest rates based on LIBOR or an alternate base rate. The company was in compliance with its debt covenants at March 31, 2017.
The company paid $2.355 million in dividends during fiscal 2017, or $0.16 per share per quarter. No shares were repurchased during the fourth quarter or fiscal year.
Material changes versus the prior comparable period
- Revenue increased 11%, driven mainly by acquisitions and growth in Biological Indicators and Cold Chain Packaging.
- Organic revenue growth was 5%: Biological Indicators increased 7% and Cold Chain Packaging increased 85%, while Instruments declined 4% and Cold Chain Monitoring declined 2%.
- Biological Indicators revenue rose 15% to $38.635 million, including 95% growth in service revenue.
- Instruments revenue declined 4% to $34.405 million, partly because fiscal 2016 included a large one-time order and accelerated order timing.
- Cold Chain Monitoring revenue increased 9% to $12.584 million, primarily due to the FreshLoc acquisition, despite a 2% organic decline.
- Cold Chain Packaging revenue increased 114% to $8.041 million, but its gross margin fell to 25% from 48% due largely to a large discounted customer contract.
- Operating cash flow declined primarily because of $9.554 million of contingent-consideration payments and $3.066 million of payments for accrued salaries, taxes, and other liabilities.
- General and administrative expense decreased 3%, primarily because fiscal 2016 included a $1.709 million Amato litigation-settlement charge.
- Other expense increased to $2.017 million from $0.768 million, including a $0.450 million additional PCD earn-out accrual and higher interest expense.
Guidance, outlook, risks, and unusual items
Management expects continued growth through organic initiatives and acquisitions. It stated that Biological Indicators and Cold Chain Packaging markets remain strong, while Instruments and Cold Chain Monitoring are more exposed to economic conditions and customer capital-spending decisions. Management expects Cold Chain Packaging to continue growing but cautioned that its 85% organic growth rate is unlikely to continue in fiscal 2018. Management also expects new products from all divisions during the following year.
- The company is consolidating Biological Indicator operations from Omaha and Traverse City into a new Bozeman facility. Total relocation costs are estimated at $2.1 million, of which $0.725 million was recognized in fiscal 2017. Annual savings are estimated at approximately $0.6 million after completion.
- The company spent $9.632 million on the new Bozeman facility during fiscal 2017 and estimated approximately $1.0 million of remaining construction costs. It expects potential proceeds of $3 million to $4 million from selling the old Bozeman and Omaha buildings.
- Goodwill and net intangible assets totaled $72.156 million and $37.790 million, respectively. No impairment charges were recorded for fiscal 2017, 2016, or 2015.
- Variable-rate debt exposes the company to interest-rate risk; management estimated that a one-percentage-point rate increase would raise annual interest expense by approximately $0.5 million.
- Key risks include economic cyclicality, competition, dependence on acquisitions, acquisition integration and earn-outs, FDA and other regulatory requirements, product liability, supply-chain disruption, foreign exchange, cybersecurity, tax matters, litigation, and potential goodwill or intangible-asset impairment.
- The PCD contingent consideration liability remains subject to adjustment based on final revenue performance. The company also has $4.978 million of purchase commitments, primarily due within one year.
- The company expects to adopt the new revenue-recognition standard on a modified retrospective basis beginning April 1, 2018 and preliminarily expects no material financial-statement impact.
Important facts for investors to verify
- Confirm that the intended period is fiscal 2017 rather than “2015 Q4,” because the supplied document is a fiscal 2017 annual filing.
- Assess whether revenue growth is sustainable after separating organic growth from acquisitions and the unusually strong Cold Chain Packaging performance.
- Review the decline in gross and operating margins, including relocation costs, inventory reserves, product mix, and discounted customer contracts.
- Evaluate debt-service capacity, variable-rate exposure, covenant compliance, and the March 2022 debt maturity concentration.
- Reconcile operating cash flow with net income after contingent-consideration payments and elevated capital expenditures.
- Monitor relocation execution, remaining costs, expected savings, and potential proceeds from facility sales.
- Review goodwill, intangible assets, acquisition earn-outs, and assumptions supporting future impairment testing.
- Consider regulatory, product-quality, cybersecurity, foreign-currency, tax, litigation, and acquisition-integration risks.